








Pyoderma gangrenosum (PG) is a rare dermatosis with  uncertain etiology, often difficult to diagnose and associated to 
Inflammatory bowel disease. Skin ulcers form rapidly and progressively, most commonly the pretibial region. There is no standard 
treatment or simple algorithm for the choice of therapy. We describe a clinical case of a giant ulcer of the abdominal wall caused 
by pyoderma gangrenosum in a patient with ulcerative colitis.
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Pyoderma gangrenosum (PG) is a dermatological condition 
characterized by painful, sterile, necrotizing ulcerations  which 
commonly the pretibial region as well as peristomal sites.1 The  
incidence is 0.31.0/100,000  and occurs between the ages of 20 
and 50 years with women being more often affected than men.2-
3 PG makes up approximately 13 % of extraintestinal 
manifestations in IBD patients (Inflammatory bowel disease IBD : 
ulcerative colitis, Crohn's disease). There is evidence for PG to be 
considered among the group of autoinflammatory diseases. There 
is no uniform therapeutic standard, but new therapeutic 
approaches, the  targeted therapies, have higher efficacy and a 
5
lower rate of side effects than conventional immunosuppressants.
CASE REPORT
A 66-year-old woman with an history of ulcerative colitis, was 
admitted to our department of Surgery due a giant painful ulcer on 
abdominal wall of 12 cm × 22 cm (Figures 1-2). She was initially 
treated in a primary care center with antibiotics and debridement 
of the ulcer. Blood investigations showed a white blood cell count 
of 15.000 cells/mm2, C-reactive protein level of 115 mg/l.  Wound 
swab was taken, the necrotic patch was debrided totally, and 
tissue and blood culture samples were sent. Empirical antibiotic 
therapy was  started as per hospital protocol. All the culture 
reports were sterile. A dermatology opinion was sought and a 
clinical suspicion of pyoderma gangrenosum was made which was 
confirmed with the tissue biopsy. The patient was started on oral 
steroids under antibiotic coverage, and the daily dressing was 
done. The ulcer stopped spreading further, and she improved 
significantly (Figures 3-4). She is now kept on regular follow-up.
DISCUSSION
Pyoderma gangrenosum is a diagnosis of exclusion and can only be 
made after common causes of ulcers such as infection and 
malignancy have been ruled out.6 Clinically, it can be mistaken as 
necrotizing fasciitis, hidradenitis suppurativa, or herpes infection 
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and is unresponsive to antibiotic therapy.  The mainstay of 
11
treatment is long-term immunosuppression.  However, response 
rates are highly variable, and only a sub-group of patients actually 
benefi ts from treatment. Corticosteroids are the most commonly 
used systemic agents for the treatment of PG, and are usually given 
at a dose of 0.52 mg/kg every day, depending on disease 
12-13
severity.  A subgroup of patients, who only insufficiently 
respond to conventional immunosuppressants, may respond to 
novel therapies, such as TNF α  inhibitors, and the target 
therapies,  such as uste-kinumab, anakinra, and the monoclonal 
IL-1 β  antibody cana-kinumab  and possibly even to IL-17 
10
antagonists. 
Figure 1                                       Figure 2
Figure 3                                        Figure 4
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